Silyamandin
CAS No. 1009565-36-9
Silyamandin( —— )
Catalog No. M31943 CAS No. 1009565-36-9
Silyamandin may have antihepatotoxic and chemopreventive activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 351 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSilyamandin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSilyamandin may have antihepatotoxic and chemopreventive activities.
-
DescriptionSilyamandin may have antihepatotoxic and chemopreventive activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1009565-36-9
-
Formula Weight498.4
-
Molecular FormulaC25H22O11
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Cajanin
Cajanin has potential hypolipidemic effects,possibly via up-regulating the ABCA1 protein expression,subsequently resulting in increased macrophage cholesterol efflux and RCT, it can significantly improve basal glucose uptake in HepG2 cells, its improving effect is concentration dependent, it exhibits effects stronger than that of rosiglitazone, which has been used as an antidiabetic drug.
-
BDC2.5 mimotope 1040...
BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice.This is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. from non-obese diabetic (NOD) mice. T cells from prediabetic and diabetic NODs respond to BDC2.5 mimotope peptides.
-
H-Arg-Arg-Leu-Ile-Gl...
pp60v-src Autophosphorylation site is a synthetic peptide. pp60v-src Autophosphorylation site can be used for various biochemical studies.
Cart
sales@molnova.com